Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
The AXL receptor and its activating ligand, growth arrest–specific 6 (GAS6) , are important drivers of metastasis and therapeutic resistance in human cancers. Given the critical roles that GAS6 and AXL play in refractory disease, this signaling axis represents an attractive target for therapeutic intervention. However, the strong picomolar binding affinity between GAS6 and AXL and the promiscuity of small molecule inhibitors represent important challenges faced by current anti-AXL therapeutics. However, these barriers can be overcome by designing second generation high affinity AXL decoy receptors.